{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:10:34Z","timestamp":1788441034797,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejps.2025.107382","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:51:58Z","timestamp":1763639518000},"page":"107382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The influence of dapagliflozin on diabetic ocular complications: An observational cohort study"],"prefix":"10.1016","volume":"216","author":[{"given":"Jo-Hsin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Mei","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2838-6596","authenticated-orcid":false,"given":"Jong-Shiuan","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10365","key":"10.1016\/j.ejps.2025.107382_bib0001","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejps.2025.107382_bib0002","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/archopht.126.7.986","article-title":"Identification of patients with diabetic macular edema from claims data: a validation study","volume":"126","author":"Bearelly","year":"2008","journal-title":"Arch Ophthalmol."},{"issue":"5","key":"10.1016\/j.ejps.2025.107382_bib0003","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s13300-022-01237-9","article-title":"Beyond the glycaemic control of Dapagliflozin: microangiopathy and non-classical complications","volume":"13","author":"Bellido","year":"2022","journal-title":"Diabetes Ther."},{"issue":"10","key":"10.1016\/j.ejps.2025.107382_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224549","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: a real-world Korean study","volume":"14","author":"Chung","year":"2019","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.ejps.2025.107382_bib0005","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejps.2025.107382_bib0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejps.2025.107382_bib0007","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/cpt.3074","article-title":"Risk of diabetic retinopathy in patients with type 2 diabetes after SGLT-2 inhibitors: a nationwide population cohort study","volume":"115","author":"Huang","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ejps.2025.107382_bib0008","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.2337\/dc18-1355","article-title":"Retinopathy outcomes with Empagliflozin versus Placebo in the EMPA-REG OUTCOME trial","volume":"42","author":"Inzucchi","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ejps.2025.107382_bib0009","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaophthalmol.2019.0900","article-title":"Association of Statin use and high serum cholesterol levels with risk of primary open-angle glaucoma","volume":"137","author":"Kang","year":"2019","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107382_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/XCE.0000000000000209","article-title":"Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond","volume":"10","author":"Lahoti","year":"2021","journal-title":"Cardiovasc. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.ejps.2025.107382_bib0011","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaophthalmol.2017.1595","article-title":"Accuracy of billing codes used in the therapeutic care of diabetic retinopathy","volume":"135","author":"Lau","year":"2017","journal-title":"JAMA Ophthalmol."},{"issue":"10","key":"10.1016\/j.ejps.2025.107382_bib0012","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.2337\/dc20-3133","article-title":"Sodium\u2013Glucose cotransporter 2 inhibitors and risk of retinal vein occlusion among patients with type 2 diabetes: a propensity score\u2013matched cohort study","volume":"44","author":"Lee","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ejps.2025.107382_bib0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis."},{"issue":"1","key":"10.1016\/j.ejps.2025.107382_bib0014","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/dom.14197","article-title":"Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"23","author":"Li","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.ejps.2025.107382_bib0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4093\/dmj.2022.0221","article-title":"Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"47","author":"Lin","year":"2023","journal-title":"Diabetes Metab. J."},{"issue":"7","key":"10.1016\/j.ejps.2025.107382_bib0016","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/17512433.2022.2102973","article-title":"The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis","volume":"15","author":"Ma","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"21","key":"10.1016\/j.ejps.2025.107382_bib0017","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejps.2025.107382_bib0018","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0161-6420(97)30247-4","article-title":"Open-angle Glaucoma and diabetes: the blue mountains eye study, Australia","volume":"104","author":"Mitchell","year":"1997","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ejps.2025.107382_bib0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamaophthalmol.2013.577","article-title":"Accuracy of international classification of diseases, ninth revision, clinical modification billing codes for common ophthalmic conditions","volume":"131","author":"Muir","year":"2013","journal-title":"JAMA Ophthalmol."},{"issue":"17","key":"10.1016\/j.ejps.2025.107382_bib0020","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1080\/14656566.2021.1953471","article-title":"Dapagliflozin for the treatment of type 2 diabetes mellitus - an update","volume":"22","author":"Nicholson","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"issue":"9","key":"10.1016\/j.ejps.2025.107382_bib0021","article-title":"Prevalence and associated risk factors of primary open angle glaucoma among patients with type 2 diabetes mellitus: a cross-sectional study from North India","volume":"14","author":"Singh","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ejps.2025.107382_bib0022","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jamaophthalmol.2016.5406","article-title":"Association of daily dosage and type of statin agent with risk of open-angle glaucoma","volume":"135","author":"Talwar","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ejps.2025.107382_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3801570","article-title":"Ocular complications of diabetes and therapeutic approaches","volume":"2016","author":"Vieira-Potter","year":"2016","journal-title":"Biomed. Res. Int."},{"issue":"22","key":"10.1016\/j.ejps.2025.107382_bib0024","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.3390\/ijms20225668","article-title":"Lessons from the trials for the desirable effects of sodium glucose Co-transporter 2 inhibitors on diabetic cardiovascular events and renal dysfunction","volume":"20","author":"Wakisaka","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ejps.2025.107382_bib0025","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/hh1101.091265","article-title":"Sodium-coupled glucose transporter as a functional glucose sensor of retinal microvascular circulation","volume":"88","author":"Wakisaka","year":"2001","journal-title":"Circ Res."},{"issue":"8","key":"10.1016\/j.ejps.2025.107382_bib0026","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/glycob\/cwx047","article-title":"Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy","volume":"27","author":"Wakisaka","year":"2017","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.ejps.2025.107382_bib0027","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ejps.2025.107382_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.48431","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes","volume":"6","author":"Yen","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.ejps.2025.107382_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-38957-2","article-title":"Association between statin use and open-angle glaucoma: a nested case-control study using the Japanese claims database","volume":"13","author":"Yokoyama","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejps.2025.107382_bib0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2014.07.051","article-title":"Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis","volume":"122","author":"Zhao","year":"2015","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ejps.2025.107382_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102972","article-title":"Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T19:23:28Z","timestamp":1766777008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"alternative-id":["S0928098725003793"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107382","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The influence of dapagliflozin on diabetic ocular complications: An observational cohort study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107382"}}